FDA clears first-of-a-kind device for brain cancer

Apr 15, 2011

(AP) -- Medical device maker Novocure says it has received U.S. approval for a first-of-a-kind treatment which fights cancerous brain tumors using electrical energy fields.

The Food and Drug Administration has approved the device for patients with aggressive brain cancer that has returned after treatment with chemotherapy. Patients with recurring brain cancer usually live only a few months.

For decades doctors have treated cancer with drugs, and surgery. Novocure's NovoTTF offers a fourth approach. The portable device uses electric fields to disrupt the division of that allows tumors to grow. It sends the signals through four electrodes which are taped to the patient's head.

A 237-patient study showed that people using the device lived about as long as those taking . However, patients had significantly fewer side effects.

Explore further: Survival differences seen for advanced-stage laryngeal cancer

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Clinical Trial to Treat Brain Tumors with Electric Fields

Jun 04, 2010

(PhysOrg.com) -- The University of Illinois at Chicago is taking part in an international, multi-center study for patients newly diagnosed with the most common and aggressive type of brain tumor, glioblastoma multiforme, ...

Clinical trial evaluating brain cancer vaccine is underway

Oct 19, 2007

A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center. The study will evaluate the addition of the vaccine following standard therapy with surgery ...

Drug combination shrinks breast cancer metastases in brain

Dec 16, 2007

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.